LEVETIRACETAM TEVA ® 250 MG

البلد: إسرائيل

اللغة: الإنجليزية

المصدر: Ministry of Health

العنصر النشط:

LEVETIRACETAM 250 MG

متاح من:

TEVA PHARMACEUTICAL INDUST.LTD

ATC رمز:

N03AX14

الشكل الصيدلاني:

TABLETS

طريقة التعاطي:

PER OS

المصنعة من قبل:

TEVA PHARMACEUTICAL INDUSTRIES LTD

المجموعة العلاجية:

LEVETIRACETAM

الخصائص العلاجية:

- Levetiracetam is indicated as adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adults and children from 4 years of age with epilepsy. - Levetiracetam is indicated as adjunctive therapy in the treatment of myoclonic seizures in adults and adolescents from 12 years of age with Juvenile Myoclonic Epilepsy.- Levetiracetam is indicated as monotherapy in the treatment of partial onset seizures with or without secondary generalisation in patient from 16 years of age with newly diagnosed epilepsy.- Levetiracetam is indicated in the treatment of primary gneralized tonic-clonic seizures in adults and adolescents from 12 years of age with idiopathic generalised epilepsy.

تاريخ الترخيص:

2009-09-01